Enhancing Lentiviral Vector Titre By Limiting Auto-Transduction

By Harry Jenkins, Jodi Twitchen, Sherin Parokkaran Johny, Meenakshi Raghunath, Matthew Peckett, Jade Thomason, Hannah Dunn, Maria Ababi, Keith Meaney, Maria Patrício, Qian Liu, Matthew Tridgett

High-titre lentiviral vector (LVV) production is critical for the success of cell and gene therapies, yet a significant challenge lies in auto-transduction, the unintended reintegration of newly produced LVVs into the producer cell line. This process reduces overall yield and efficiency, particularly in extended or continuous manufacturing workflows. Recent findings demonstrate that introducing Additive X during LVV production can dramatically mitigate this issue. By inhibiting auto-transduction, Additive X not only prevents reintegration events but also enhances infectious titre by an impressive 4.2-fold. Studies further reveal that timing matters: adding Additive X 48 hours post-seeding delivers superior results compared to induction-day supplementation.

Additionally, reduced vector copy numbers in both producer and transduced cells confirm its mechanism of action. For manufacturers aiming to scale LVV-based therapies, especially in continuous production environments, this approach offers a promising solution to maximize yield and maintain process consistency.

Learn how this optimization strategy can transform LVV manufacturing efficiency and support the growing demand for advanced therapies.